NASDAQ:DARE • US23666P2002
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DARE BIOSCIENCE INC (DARE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-04 | Maxim Group | Upgrade | Hold -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | Jones Trading | Maintains | Buy -> Buy |
| 2024-08-14 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-05-15 | Brookline Capital | Upgrade | Hold -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-17 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-13 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-01 | JonesTrading | Initiate | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10M | 2.808M -71.92% | 9.8K -99.65% | 385.815K 3,836.89% | 33.953M 8,700.33% | 66.522M 95.92% | 166.79M 150.73% | 280.07M 67.92% | 419.33M 49.72% | 551.98M 31.63% | 679.54M 23.11% | 782.06M 15.09% | |
| EBITDA YoY % growth | -31.37M 19.65% | -30.902M 1.49% | -23.409M 24.25% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -31.39M 19.66% | -30.94M 1.43% | -23.452M 24.20% | -18.37M 21.67% | -17.75M 3.37% | 31.665M 278.39% | 123.27M 289.29% | 220.49M 78.87% | 334.26M 51.60% | 461.93M 38.19% | 573.65M 24.19% | 665.66M 16.04% | |
| Operating Margin | -313.90% | -1,101.89% | -239,301.02% | -4,761.34% | -52.28% | 47.60% | 73.91% | 78.73% | 79.71% | 83.69% | 84.42% | 85.12% | |
| EPS YoY % growth | -4.44 47.89% | -4.08 8.11% | -0.52 87.25% | -1.68 -223.65% | -0.36 78.79% | 0.93 360.00% | 4.18 350.00% | 6.74 61.29% | 10.65 58.06% | 14.68 37.88% | 18.19 23.86% | 20.84 14.58% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 32.13% | -0.37 26.56% | -0.37 17.27% | 0.48 271.21% | 0.43 197.11% | 0.12 133.33% | 0.13 135.62% | 0.14 -70.21% | 0.15 -64.29% |
| Revenue Q2Q % growth | 383.265K 698.85% | 1.607M 6,219.31% | 2.428M 11,661.90% | 16.056M 802,700.00% | 9.329M 2,334.09% | 10.009M 522.84% | 10.444M 330.15% | 11.315M -29.53% | 11.749M 25.94% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.595M -3.85% | -6.054M -32.15% | -6.317M -21.33% | -6.843M -86.35% | -7.106M -27.00% | 1.507M 124.89% | 1.572M 124.89% | 1.703M 124.89% | 1.769M 124.89% |
All data in USD
10 analysts have analysed DARE and the average price target is 10.97 USD. This implies a price increase of 661.46% is expected in the next year compared to the current price of 1.44.
DARE BIOSCIENCE INC (DARE) will report earnings on 2026-03-30, after the market close.
The consensus EPS estimate for the next earnings of DARE BIOSCIENCE INC (DARE) is -0.44 USD and the consensus revenue estimate is 383.26K USD.
The consensus rating for DARE BIOSCIENCE INC (DARE) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.